Ciclindole (INN; developmental code name WIN-27,147-2), also known as cyclindole (USAN), is an antipsychotic with a tricyclic and tryptamine-like structure that was never marketed.[1][2]
 | |
| Clinical data | |
|---|---|
| Other names | WIN-27,147-2; WIN-27147-2; WIN27147-2 |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H18N2 |
| Molar mass | 214.312 g·mol−1 |
| 3D model (JSmol) | |
| |
It displaces spiperone binding in vitro and elevates dopamine levels in the striatum, indicating that it acts as a dopamine D2 receptor antagonist.[2] It also shows apparent affinity for the α1-adrenergic receptor, the serotonin S1 receptor, and the serotonin S2 receptor.[2] However, its affinities for all of the preceding targets are weak, in the low micromolar range.[2]
The related drug flucindole is about 5 to 10 times more potent than ciclindole both in vitro and in vivo.[2]
See also
editReferences
edit- ^ Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
- ^ a b c d e Wood PL, McQuade PS (1984). "Ciclindole and flucindole: novel tetrahydrocarbazolamine neuroleptics". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 8 (4–6): 773–7. doi:10.1016/0278-5846(84)90057-5. PMID 6152347. S2CID 39252411.